The impact of semaglutide use for weight loss on transforaminal lumbar interbody fusion outcomes

This publication has 28 references indexed in Scilit:

• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
  JAMA, 2024
• Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity
  Calcified Tissue International, 2023
• Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
  JAMA, 2023
• Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
  JAMA, 2021
• Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
  JAMA, 2021
• Preoperative paraspinal neck muscle characteristics predict early onset adjacent segment degeneration in anterior cervical fusion patients: A machine‐learning modeling analysis
  Journal of Orthopaedic Research, 2020
• Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
  Obesity, 2020
• Impact of obesity on outcomes following lumbar spine surgery: A systematic review and meta-analysis
  Clinical Neurology and Neurosurgery, 2019
• Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials
  Osteoporosis International, 2018
• Minimally invasive versus open transforaminal lumbar fusion: a systematic review of complications
  International Orthopaedics, 2016